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Abstract
Background: The aim of this study was to assess the effects of soluble sialic acid-binding immunoglobulin-type
lectin (sSiglec)-9 on joint inflammation and destruction in a murine collagen-induced arthritis (CIA) model and in
monolayer cultures of murine macrophages (RAW264.7 cells and peritoneal macrophages) and fibroblast-like
synoviocytes (FLS) derived from patients with rheumatoid arthritis.
Methods: DBA/1J mice were immunized with type II collagen. Effects of sSiglec-9 were evaluated using a physiologic
arthritis score, histological analysis, serum tumor necrosis factor (TNF)-α concentration, and the proportion of forkhead
box P3 (Foxp3)-positive regulatory T (Treg) cells. In vivo biofluorescence imaging was used to assess the distribution of
sSiglec-9. Levels of M1 (TNF-α, interleukin [IL]-6, and inducible nitric oxide synthase) and M2 (CD206, Arginase-1, and
IL-10) macrophage markers and phosphorylation of intracellular signaling molecules were examined in macrophages,
and levels of matrix metalloproteinase (MMP)-1, MMP-3, and MMP-13 were examined in FLS.
Results: sSiglec-9 significantly suppressed the clinical and histological incidence and severity of arthritis. The proportion
of Foxp3-positive Treg cells significantly improved and serum TNF-α concentration decreased in vivo. Although
sSiglec-9 reduced the expression of M1 markers in macrophages, it did not affect the expression of M2 markers
and MMPs in FLS. Nuclear factor (NF)-kB p65 phosphorylation was attenuated by sSiglec-9, and chemical blockade of
the NF-kB pathway reduced M1 marker expression in RAW264.7 cells.
Conclusions: In this study, we have demonstrated the therapeutic effects of sSiglec-9 in a murine CIA model. The
mechanism underlying these effects involves the suppression of M1 proinflammatory macrophages by inhibiting the
NF-kB pathway. sSiglec-9 may provide a novel therapeutic option for patients with rheumatoid arthritis refractory to
currently available drugs.
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Background
Rheumatoid arthritis (RA) is a common autoimmune dis-
ease characterized by chronic synovial joint inflammation,
including synovial hyperplasia, infiltration of inflammatory
cells, fibrin deposition, and joint destruction [1]. Proin-
flammatory cytokines and proteases secreted from syn-
ovial tissue alter chondrocyte metabolism and cartilage
matrix degradation, leading to cartilage destruction.
Recent evidence suggests that the standard treatment
strategies, including methotrexate-based conventional
disease-modifying antirheumatic drugs (DMARDs) and
biological DMARDs, significantly suppress disease activity
and joint destruction in patients with RA. However, these
strategies target only certain patient populations [2], and
thus there is an unmet need for new antirheumatic drugs
with novel mechanisms of action.
Synovial cells in the RA synovial membrane consist of
synovial fibroblasts, macrophages, and lymphocytes.
Macrophages in inflamed synovial tissue play a central
role in the sustenance of synovial inflammation and pro-
motion of tissue destruction [3–5]. Macrophages differ-
entiate from peripheral blood monocytes and express
adhesion molecules, chemokine receptors, and other
surface antigens, as well as cytokines and chemokines
that maintain joint inflammation [6–9]. This suggests
that macrophages and their products are promising
therapeutic targets in patients with RA.
Sialic acid-binding immunoglobulin-type lectins
(Siglecs) are type I transmembrane proteins that bind to
sialic acid. They are I-type (immunoglobulin [Ig]-type) lec-
tins that belong to the Ig superfamily and are expressed
on the cell surface of various immunocytes [10, 11].
Siglecs have a characteristic N-terminal, Ig-like, V-type do-
main that mediates binding to sialic acid, as well as vary-
ing numbers of Ig-like, C2-type domains (2–17), a single
transmembrane region, and a cytoplasmic tail (except for
Siglec-1 and Siglec-14). Siglec-9 is a member of the CD33-
related Siglecs in humans and corresponds to Siglec-E
expressed on murine immunocytes. Siglec-9 downregu-
lates both innate and acquired immune responses, and has
immunoreceptor tyrosine-based inhibitory motifs in the
cytosolic region [12]. As a receptor, Siglec-9 induces the
production of low levels of tumor necrosis factor (TNF)-α
upon stimulation with lipopolysaccharide (LPS) and en-
hances the production of the anti-inflammatory cytokine
interleukin (IL)-10 in macrophages [13]. Siglec-9 was re-
cently identified as a candidate ligand on leukocytes [14].
Matsubara et al. [15] reported that the extracellular
domain of Siglec-9 (soluble Siglec-9 [sSiglec-9]) and
monocyte chemoattractant protein 1 (chemokine [C-C
motif] ligand 2 [CCL2]) induce functional recovery in a
rat spinal cord injury (SCI) model. They found that
sSiglec-9 exerts anti-inflammatory effects at the spinal
injury site by altering macrophage polarization from being
M1-dominant (proinflammatory) to M2-dominant (anti-
inflammatory). They concluded that sSiglec-9 and CCL2
are inducers of M2 macrophages and promote functional
recovery via their anti-inflammatory effects at the SCI site.
In this study, we used a mouse collagen-induced arth-
ritis (CIA) model to investigate the therapeutic effects of
sSiglec-9 in arthritis and subsequent joint destruction in
vivo. We also conducted in vitro studies to evaluate the
anti-inflammatory effects of sSiglec-9 in murine macro-
phages (RAW264.7 cells and peritoneal macrophages
[pMACs]) and human fibroblast-like-synoviocytes (FLS).
Methods
Reagents
Recombinant human Siglec-9 and interferon (IFN)-γ
were purchased from R&D Systems (Minneapolis, MN,
USA). Recombinant human TNF-α was obtained from
PeproTech (Rocky Hill, NJ, USA). Complete Freund’s
adjuvant (CFA) was purchased from Chondrex (Red-
mond, WA, USA). Bovine type II collagen was obtained
from Seikagaku (Tokyo, Japan).
CIA model
All animal experiments were performed in accordance
with the National Institutes of Health Guide for the Care
and Use of Laboratory Animals and with the approval of
our institutional animal ethics committee (Division of
Experimental Animals, Nagoya University, and Center
for Animal Research and Education, Nagoya University).
Seven-week-old male DBA/1J mice were purchased
from Japan SLC (Hamamatsu, Japan). Mice were immu-
nized subcutaneously at the base of the tail with 100 μl
of bovine type II collagen (2 mg/ml) dissolved in 0.01 M
acetic acid emulsified 1:1 with CFA; ultimately, each
mouse received 100 μg of bovine type II collagen. Mice
further received a subcutaneously administered booster
tail injection of 50 μg of bovine type II collagen emulsi-
fied in incomplete Freund’s adjuvant 21 days later
(Fig. 1a).
sSiglec-9 treatments
Mice (n = 23) were randomly allocated to three groups be-
fore immunization: a control CIA group (n = 8) and two
treatment groups with human sSiglec-9 at a dose of 5 ng/g
body weight (n = 7) or 50 ng/g body weight (n = 8). Mice
were intravenously administered 100 μl of PBS in the con-
trol CIA group or sSiglec-9 (5 or 50 ng/g body weight in a
total volume of 100 μl) in the treatment groups weekly
from days 23 to 37 (primary immunization day was set as
day 0) (Fig. 1a). This schedule was based on preliminary re-
sults showing that arthritis almost always developed by day
23 when the above protocol was used (data not shown).
These in vivo experiments were performed twice independ-
ently with reproducible results.
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Clinical and histological evaluation
CIA was considered to have successfully developed and
was regarded as incident when swelling was observed in
at least one digit or paw. The severity of arthritis was
graded in each paw on a 0- to 3-point scale as follows:
grade 0 = normal, grade 1 = swelling of one digit, grade
2 = swelling of two digits, and grade 3 = swelling of the
entire paw (Fig. 1e). The cumulative score for four paws
Fig. 1 Effects of soluble sialic acid-binding immunoglobulin-type lectin (sSiglec)-9 on arthritis symptoms in mice with collagen-induced arthritis
(CIA). a Postinjection (24 h, non-CIA versus CIA) images with VivoTag 680 XL-labeled sSiglec-9. Accumulation of fluorescence in CIA joints is
denoted by dashed red circles. b Representative images of hind paws from each treatment group. c Cumulative incidence of arthritis in control
CIA mice (untreated) and mice treated with different dosages of sSiglec-9. *p < 0.05 for sSiglec-9 50 ng/g versus control (χ2 test). d Severity of
arthritis symptoms as evaluated using the arthritis score in control CIA mice (untreated) and mice treated with different dosages of soluble
sSiglec-9. *p < 0.05 for sSiglec-9 50 ng/g versus control (Bonferroni post hoc test). e Serum tumor necrosis factor (TNF)-α concentration was
significantly decreased in mice treated with 50 mg/g sSiglec-9. *p < 0.05 (Bonferroni post hoc test). f Arthritis score and serum TNF-α concentration
were strongly and positively correlated (p < 0.01, R = 0.837 [Pearson product-moment correlation coefficient])
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of each mouse was used as the arthritis score (maximum
score of 12 per mouse) to represent overall disease se-
verity and progression [16]. We calculated the cumula-
tive incidence of arthritis, excluding dropouts, during
the experimental period.
On day 42, mice were killed under general anesthesia
by systemic perfusion of 4 % paraformaldehyde. The bi-
lateral knee and ankle joints of all mice were dissected
and subjected to histological analysis. Histopathological
changes in the joints were scored using parameters de-
scribed in previous reports [17, 18]. Four parameters of
histological scores were assessed separately (n = 8 each
group): inflammation (synovitis), pannus formation, car-
tilage degeneration, and bone degeneration. We evalu-
ated each parameter as follows: normal = 0, mild = 1,
moderate = 2, and severe = 3. The sum of the bilateral
scores was calculated (maximum score per mouse = 6).
We collected blood from the hearts of mice, and the
serum concentration of TNF-α was determined using an
enzyme-linked immunosorbent assay (ELISA) assay kit
(BioLegend, San Diego, CA, USA) according to the man-
ufacturer’s instructions.
Immunohistochemical analysis
Ankle joint sections were subjected to immunohisto-
chemical analysis using specific antibodies. The primary
antibodies used were mouse anti-TNF-α antibody (1:100
dilution; Abcam, Cambridge, UK), mouse anti-IL-6 anti-
body (1:100 dilution; Abcam), and antimouse inducible
nitric oxide synthase (iNOS) polyclonal antibody (1:1000
dilution; Wako Pure Chemical Industries, Osaka, Japan).
Histofine® Simple Stain MAX PO (Nichirei Biosciences,
Tokyo, Japan) was used as the secondary antibody.
Stained sections incubated without primary antibodies
were used as negative controls.
CD4+ T-cell isolation, intracellular staining, and flow
cytometry
Spleens from mice were collected for cell preparation and
washed twice with PBS. Spleens were minced, and red
blood cells were lysed with 0.83 % ammonium chloride.
The cells were filtered through a cell strainer and centri-
fuged at 1300 revolutions per minute for 5 minutes at 4 °C.
To purify splenic CD4+ T cells, splenocytes were incubated
with CD4-coated magnetic beads and isolated using the
EasySep isolation kit (STEMCELL Technologies,
Vancouver, BC, Canada), and viable CD3+CD4+ T cells
were collected as previously described [19].
Allophycocyanin-conjugated anti-CD25 antibody
(eBioscience, San Diego, CA, USA) and anti-forkhead
box P3 (Foxp3) antibody (Cell Signaling Technology,
Danvers, MA, USA) were used for intracellular stain-
ing and flow cytometry. Fluorescence-activated cell
sorting analysis was performed using a BD FACSCanto
II flow cytometer (BD Biosciences, San Jose, CA,
USA). All data were analyzed using FACSDiva soft-
ware (BD Biosciences).
In vivo biofluorescence imaging
In vivo biofluorescence imaging was performed to visu-
ally analyze the distribution of sSiglec-9. We used CIA
mice (on day 40 after first immunization, n = 3) and
non-CIA (n = 3) DBA/1J mice for this imaging study.
All mice were fasted overnight before imaging. sSiglec-
9 labeled with VivoTag 680 XL (VT) fluorochrome
(PerkinElmer, Waltham, MA, USA) was injected intra-
venously via the tail vein (50 ng/g body weight). VT is
an amine-reactive near-infrared fluorochrome used to
label biomolecules for in vivo imaging applications
(peak excitation 670 nm, peak emission 688 nm. One
day before imaging, sSiglec-9 was labeled with VT
using the VivoTag protein labeling kit (PerkinElmer)
according to the manufacturer’s instructions. All mice
were imaged at 6 and 24 h after injection.
Before imaging time points, mice were anesthetized
with isoflurane and oxygen, and images were captured
with them in the supine position from the dorsal aspect
using the Maestro GNIR fluorescence imaging system
(PerkinElmer). The filter (excitation and emission) and
exposure time settings were determined according to
methods described in previous studies [20, 21].
Isolation of peritoneal macrophages
pMACs were isolated from DBA/1J mice, and 5 % thio-
glycollate (2 ml; Sigma-Aldrich, St. Louis, MO, USA)
was injected into the abdominal cavity to activate
pMACs. After 3 days, mice were killed and 10 ml of
cold, sterile PBS was injected intraperitoneally. Periton-
eal lavage fluid was collected using sterile syringes and
centrifuged to obtain the pMAC cell pellet.
Cell culture
The murine macrophage cell line RAW264.7 was pur-
chased from DS Pharma Biomedical (Osaka, Japan).
RAW264.7 cells and pMACs were cultured as mono-
layers in six-well plates (1 × 105 cells/well), stimulated
with 10 ng/ml IFN-γ, and concurrently treated with
sSiglec-9 (0–10 ng/ml) for 12 h.
Isolation and culture of FLS
FLS were isolated from the synovial tissue of five pa-
tients with RA who had undergone knee joint replace-
ment surgery. Informed consent was obtained from all
patients, and our institutional ethics committee ap-
proved the study. Tissue specimens from patients were
subjected to monolayer culture according to a previously
described protocol [22]. FLS were cultured in six-well
plates (1 × 105 cells/well), stimulated with 10 ng/ml
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TNF-α, and concurrently treated with sSiglec-9 (0–10
ng/ml) for 12 h.
Pretreatment with sialidase and CCR2 antagonist
To determine whether sialic acid and C-C chemokine
receptor type 2 (CCR2) were required to induce the
anti-inflammatory effects of sSiglec-9, we used sialidase
[23] (Roche, Basel, Switzerland) to remove sialic acid
and RS504393 (R&D Systems), a selective CCR2 antag-
onist, to inhibit the CCR2/CCL2 signaling pathway [24].
RAW264.7 cells were preincubated with 15 mU/300 μl
sialidase for 1 h and 50 μM RS504393 for 20 minutes
before stimulation.
Real-time RT-PCR
Total RNA was extracted and subjected to real-time poly-
merase chain reaction (PCR) analysis to determine the
messenger RNA (mRNA) expression of M1 macrophage
markers (TNF-α, IL-6, and iNOS), M2 macrophage
markers (CD206, Arginase-1, and IL-10), and glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) in RAW264.7
cells and pMACs. The mRNA expression of matrix
metalloproteinase (MMP)-1, MMP-3, MMP-13, IL-6,
and GAPDH was determined in FLS. The primer se-
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ELISA and Western blot analysis
The effects of sSiglec-9 on the protein expression of M1
macrophage markers (TNF-α, IL-6, and iNOS) in
RAW264.7 cells were evaluated by ELISA and Western
blot analysis. RAW264.7 cells were treated with IFN-γ in
the presence or absence of sSiglec-9 (0–20 ng/ml) for 24
h. Protein concentration was determined using the
Bradford method (Bio-Rad Laboratories, Hercules, CA,
USA). Extracted proteins were subjected to ELISA for
TNF-α (BioLegend) and IL-6 (Takara Bio, Shiga, Japan)
according to the manufacturer’s instructions. Since there
were no commercially available ELISA kits for iNOS, we
determined iNOS protein levels by Western blot analysis
(40 μg/lane) using rabbit anti-iNOS and anti-β-actin
antibodies (Cell Signaling Technology). We also exam-
ined phosphorylation levels of nuclear factor (NF)-kB
and p38 by Western blot analysis using rabbit anti-
phospho-NF-kB (p65), anti-total NF-kB (p65), anti-
phospho-p38, and anti-total p38 antibodies as primary
antibodies (Cell Signaling Technology). Cell lysates for
the evaluation of NF-kB and p38 phosphorylation were
obtained 20 minutes and 30 minutes after stimulation,
respectively. The secondary antibody used for all
Western blot analyses was an HRP-linked antirabbit IgG
antibody (Cell Signaling Technology).
Statistical analysis
Values are expressed as mean ± SEM. Statistical signifi-
cance was analyzed using Student’s t test for two-group
comparisons, analysis of variance (ANOVA) for multiple
group comparisons, Pearson’s product-moment correl-
ation coefficient (R) for relationships between pairs of
parameters, and the χ2 test for comparisons of propor-
tions. The significance of individual differences in the
multiple group comparisons was evaluated using the
Bonferroni post hoc test only if ANOVA indicated sig-
nificance. p < 0.05 was considered significant. Statistical
analyses were performed with IBM SPSS Statistics 20.0.0
for Windows software (IBM, Armonk, NY, USA).
Results
Evaluation of incidence and severity of arthritis
The results of in vivo imaging suggested that sSiglec-9
localized to inflamed tissue. The sites of accumulation of
VT-labeled sSiglec-9 corresponded to inflamed extrem-
ities (Fig. 1a). The hind paws of control CIA mice (PBS-
injected) showed severe swelling of the paws and all
digits. The hind paws and digits of mice treated with
low-dose (5 ng/g) sSiglec-9 showed mild swelling,
whereas mice treated with high-dose (50 ng/g) sSiglec-9
showed no swelling (Fig. 1b).
Incidence rates and arthritis scores were evaluated
from day 21 to day 42. Arthritis first developed on day
23 (i.e., 2 days after the second immunization). The cu-
mulative incidence rate increased day by day and plat-
eaued on day 38. Treatment of CIA mice with human
sSiglec-9 reduced the cumulative incidence rate and se-
verity (arthritis score) of arthritis in a dose-dependent
manner (Fig. 1c and d). This beneficial effect was max-
imal in mice treated with 50 ng/g sSiglec-9. There was a
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significant difference between the control group and
mice treated with 50 ng/g sSiglec-9 from day 37 to day
42 for incidence rate, and from day 36 to day 42 for the
arthritis score.
Serum concentration of TNF-α
The concentration of serum TNF-α significantly de-
creased in mice treated with sSiglec-9 compared with
the control group in a dose-dependent manner (Fig. 1e).
A strong positive correlation (p = 0.002, R = 0.837) was
found between the arthritis score and serum concentra-
tion of TNF-α (Fig. 1f ).
Histological assessment of arthritis severity
The ankle joints of control CIA mice exhibited histo-
logical changes, including synovial hyperplasia with a
large number of infiltrating inflammatory cells, pannus
formation, and severe cartilage and bone destruction.
Although the ankle joints of mice treated with 5 ng/g
sSiglec-9 showed mild synovitis and mild cartilage
damage, those of mice treated with 50 ng/g sSiglec-9
showed no evident synovitis or obvious damage to car-
tilage or bone (Fig. 2a). sSiglec-9 significantly reduced
the histological scores of all four parameters in both
knee and ankle joints in a dose-dependent manner
(Fig. 2b–e).
The effect of sSiglec-9 was remarkable in the scores of
cartilage degeneration and bone erosion, and even the 5
ng/ml dosage of sSiglec-9 reduced the scores of these
two parameters in the ankle joints.
Immunohistochemical analysis of ankle specimens
Signal intensities for TNF-α, IL-6, and iNOS in syn-
ovial membranes decreased in groups treated with
sSiglec-9 in a dose-dependent manner (Fig. 3a). The
intensities of these proteins in control CIA mice were
Fig. 2 Histological analysis of inflamed joints in mice with collagen-induced arthritis (CIA). a The severity of arthritis was evaluated histologically
in knee and ankle joint specimens obtained from control CIA mice (untreated) and mice treated with different dosages of soluble sialic acid-binding
immunoglobulin-type lectin (sSiglec)-9. Each section was stained with hematoxylin and eosin (HE; upper row) or Safranin O (lower row). Serial sagittal
sections (4.5 μm) were examined, and the maximally affected section was evaluated and scored. Typically, the midline of the medial condyle
was examined. Scale bar = 100 μm. b–e Mean ± SEM histological arthritis scores (inflammation, pannus formation, cartilage degeneration, and
bone erosion) in control CIA mice and mice treated with different dosages of sSiglec-9. *p < 0.05, ** p < 0.01 (Bonferroni post hoc test)
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stronger than those in mice treated with sSiglec-9.
The number of cells positive for TNF-α, IL-6, and
iNOS was also significantly less in groups treated with
sSiglec-9 than in control CIA mice (Fig. 3b).
Normalization of Foxp3-positive regulatory T cells in mice
treated with sSiglec-9
Flow cytometry revealed a reduced proportion of
CD25+Foxp3+ regulatory T (Treg) cells in control CIA
Fig. 3 a Immunohistochemical staining of tumor necrosis factor (TNF)-α, interleukin (IL)-6, and inducible nitric oxide synthase (iNOS) in ankle joint
specimens from control collagen-induced arthritis (CIA) mice and mice treated with different dosages of soluble sialic acid-binding immunoglobulin-type
lectin (sSiglec)-9 at low (×200 original magnification) and high (×1000 original magnification; insets) magnifications. Scale bars: black= 100 μm; red= 20 μm.
Strong positive staining was observed in control CIA mice, and weaker staining was observed in mice treated with sSiglec-9. b Immunopositive cells were
counted individually in three different areas under a light microscope at × 400 original magnification. The number of positively stained cells was then
averaged. The proportion of immunopositive cells was determined by dividing the number of positive cells by the total number of cells within the field.
sSiglec-9 treatment significantly decreased the proportion of cells positive for TNF-α, IL-6, and iNOS. Values are presented as mean ± SEM. *p< 0.05,
**p< 0.01 versus control CIA mice (Bonferroni post hoc test). c Regulatory T (Treg) cell expansion in isolated CD4+ splenocytes. Representative results of
flow cytometric analysis of Treg cells are shown. CD4+CD25+Foxp3+ expansion in isolated splenocytes of normal mice, control CIA mice, and CIA mice
treated with 50 ng/g sSiglec-9. d Isolated CD4+ T cells from splenocytes were subjected to intracellular staining of CD25 and forkhead box P3 (Foxp3) for
flow cytometric analysis. The number of CD25+Foxp3+ T cells was significantly reduced in control CIA mice compared with normal mice. This reduction
was significantly recovered in mice treated with sSiglec-9. **p< 0.01 (Bonferroni post hoc test)
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mice (8.3 ± 0.8 %) compared with the normal group
(14.4 ± 0.8 %). CIA mice treated with sSiglec-9 (50 ng/g)
showed a significant recovery of CD25+Foxp3+ Treg cells
(11.5 ± 0.6 %) (Fig. 3c and d).
sSiglec-9 reduces the levels of secreted M1 macrophage
markers in RAW264.7 cells
The described experiments above clearly demonstrated
the in vivo efficacy of sSiglec-9 in the CIA mice model.
To determine whether these effects may be mediated by
changes in secreted inflammatory cytokines, we assessed
TNF-α, IL-6, and iNOS production in RAW264.7 cells
stimulated with 10 ng/ml IFN-γ by ELISA and Western
blot analysis. Treatment with sSiglec-9 significantly re-
duced the production of TNF-α, IL-6, and iNOS in a
dose-dependent manner (Fig. 4a and b).
Effect of sSiglec-9 on NF-kB and p38/MAPK signaling
pathways
We next assessed the phosphorylation status of NF-kB
(p65) and p38/mitogen-activated protein kinase (MAPK)
to determine the signaling pathway inhibited by sSiglec-
9. Treatment with sSiglec-9 significantly reduced the
phosphorylation of NF-kB p65 in a dose-dependent
manner, but it did not affect the phosphorylation of p38/
MAPK (Fig. 4c). We also assessed the intracellular sig-
naling pathways involved in the effects of sSiglec-9 and
confirmed that phosphorylation of NF-kB p65 and p38/
MAPK increased upon stimulation of RAW264.7 cells
with IFN-γ (100 ng/ml).
Chemical inhibitors of NF-kB and p38/MAPK path-
ways were used to determine whether these pathways af-
fected the IFN-γ-induced production of TNF-α mRNA.
If NF-kB blockade does not reduce TNF-α production,
Fig. 4 a and b Protein expression of tumor necrosis factor (TNF)-α and interleukin (IL)-6 was determined by enzyme-linked immunosorbent assay,
and that of inducible nitric oxide synthase (iNOS) was determined by Western blot analysis following treatment with soluble sialic acid-binding
immunoglobulin-type lectin (sSiglec)-9 (0–20 ng/ml) for 24 h. Expression of β-actin was used as a control. The expression of all M1 markers was
significantly suppressed by sSiglec-9 treatment. *p < 0.05, **p < 0.01 (Bonferroni post hoc test). c Western blot analysis revealed that sSiglec-9 treatment
dose-dependently decreased the interferon (IFN)-γ-stimulated phosphorylation of nuclear factor (NF)-kB p65, while the phosphorylation of p38 was not
affected. d Celastrol, a specific inhibitor of NF-kB, significantly inhibited the IFN-γ-stimulated increase in TNF-α messenger RNA (mRNA) expression.
However, SB202190, a specific inhibitor of p38/mitogen-activated protein kinase, did not affect TNF-α mRNA expression. **p < 0.01 versus
samples stimulated with IFN-γ without sSiglec-9 treatment (Bonferroni post hoc test). GAPDH glyceraldehyde 3-phosphate dehydrogenase,
n.s. not significant
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there may be another pathway that sSiglec-9 inhibits in
order to reduce TNF-α production. Pretreatment with
celastrol, a specific NF-kB inhibitor, significantly sup-
pressed TNF-α expression, even at the lowest dose tested
(Fig. 4d). In contrast, pretreatment with SB202190, a
specific p38 inhibitor, did not affect IFN-γ-induced
TNF-α expression.
Influence of sialidase and CCR2 antagonist on the effects
of sSiglec-9
It was previously reported that sialic acid and CCR2 are
required for sSiglec-9 to exert its anti-inflammatory ef-
fect [15]. Thus, we examined whether these two factors
influenced the inhibitory effects of sSiglec-9 in IFN-γ-
activated RAW264.7 macrophages. To this end, we
added sialidase and the CCR2 inhibitor RS504393 to
cells and examined TNF-α, IL-6, and iNOS mRNA levels
as described above.
Pretreatment with sialidase significantly blunted the
inhibitory effect of sSiglec-9 on IFN-γ-stimulated mRNA
expression of TNF-α and IL-6. This suggested that
sSiglec-9 exerted its anti-inflammatory effect by binding
to sialic acid (Fig. 5a). Pretreatment with RS504393 did
not affect the inhibitory effect of sSiglec-9 on IFN-γ-
stimulated mRNA expression of M1 markers (Fig. 5a).
However, CCR2 blockade reduced IL-6 and iNOS mRNA
expression relative to that in the sSiglec-9-treated
groups. These findings suggest that CCR2 is unlikely to
be involved in the mechanism of action of sSiglec-9.
This finding differs from that of a previous study in a rat
SCI model [15]. These results suggested that concomi-
tant CCR2/CCL2 blockade may augment the anti-
inflammatory effects of sSiglec-9 in the CIA mouse
model.
Taken together, our results suggest that sSiglec-9 re-
quired sialic acid on the cell surface to exert its anti-
inflammatory effect. In contrast to the rat SCI model,
CCR2 was not a receptor for sSiglec-9 in the mouse CIA
model.
sSiglec-9 reduces the expression of M1 markers, but not
M2 markers, in RAW264.7 cells and pMACs
Considering potential differences between macrophage
cell lines and primary macrophages, the macrophage cell
line RAW264.7 and pMACs were treated with IFN-γ in
the absence or presence of sSiglec-9 in vitro. Moreover,
to determine whether sSiglec-9 exerts an inhibitory ef-
fect on inflammatory macrophage function, RT-PCR was
performed to assess mRNA expression of M1 markers
(TNF-α, IL-6, and iNOS) and M2 markers (CD206, Argi-
nase-1, and IL-10).
The expression of M1 markers (TNF-α, IL-6, and
iNOS) in RAW264.7 cells and pMACs was significantly
suppressed by coculture with sSiglec-9 (Fig. 5b). The
inhibitory effect of sSiglec-9 was substantial in
RAW264.7 cells, especially with respect to IL-6 expres-
sion. sSiglec-9 did not significantly affect M2 marker ex-
pression in both cell types, although only Arginase-1 and
IL-10 expression in pMACs was increased with IFN-γ
stimuli (Fig. 5c).
Effect of sSiglec-9 is not observed in human FLS derived
from patients with RA
Synovial tissues in patients with RA consist of synovial
macrophages and FLS. MMPs and IL-6 are produced by
FLS and play a major role in the destruction of cartilage
in RA joints [25, 26]. Therefore, we also examined the
inhibitory effect of sSiglec-9 on FLS stimulated with
TNF-α and evaluated the expression of MMP-1, MMP-
3, MMP-13, and IL-6 using RT-PCR.
Contrary to the macrophage data described above,
TNF-α-stimulated mRNA expression levels of MMP-1,
MMP-3, and MMP-13, as well as of IL-6, were not af-
fected by sSiglec-9 treatment in human FLS (Fig. 6a-d ).
These data suggest that synovial cells are unlikely to be
involved in the effects of sSiglec-9 and that the beneficial
effects of sSiglec-9 can be attributed to its effects on
macrophages.
Discussion
Treatment strategies for RA have improved dramatically
over the past decade. TNF inhibitors comprise an im-
portant aspect of current RA treatment, and their thera-
peutic effects were first confirmed in the CIA model, an
established animal model of RA [27]. In this study, we
found that treatment of CIA mice with sSiglec-9 sup-
pressed arthritis symptoms in vivo and had a suppressive
effect on M1 macrophage activation in vitro. New anti-
rheumatic agents with novel mechanisms of action are
likely to arise, given that patients with RA can become
resistant to multiple preexisting drugs. In this context,
sSiglec-9 could be a new option for such patients.
Treatment with sSiglec-9 effectively suppressed princi-
pal indices of arthritis in the CIA model. Specifically, the
incidence and severity of CIA were reduced, as was the
serum concentration of TNF-α. Importantly, treatment
with sSiglec-9 significantly recovered the reduced pro-
portion of Foxp3+ Treg cells in CIA mice. Foxp3+ Treg
cells are mediators of autoimmune reaction inhibition,
and a reciprocal relationship between the differentiation
of Th17 and Treg cells has been reported [28]. This sug-
gests that sSiglec-9 may be an effective treatment option
for RA by regulating the balance of Treg and Th17 cell
differentiation.
Exposure to a drug at the site of arthritis is an im-
portant consideration for the effective treatment of
RA. In this study, we found that intravenously injected
sSiglec-9 localized mainly to inflamed joints. In a
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previous study, the distribution of TNF-α inhibitors
(certolizumab pegol, adalimumab, and infliximab) in
CIA mice was evaluated using a biofluorescence
method similar to ours. In that study, all TNF-α inhib-
itors localized to inflamed tissue, mainly within the
limbs [29]. We observed enhanced penetration of
sSiglec-9 into inflamed tissue, as with the TNF-α in-
hibitors, and demonstrated the relevance of using
sSiglec-9 as a therapeutic agent to treat RA.
In the SCI model [15], sSiglec-9 alters macrophage
polarization from M1- to M2-dominant by modifying
the intracellular CCR2 signaling pathway. The M2-
dominant polarization of macrophages reduces tissue
damage, preserves descending 5-hydroxytryptamine-
positive axons, and promotes functional recovery after
SCI. M1 macrophages are involved in acute inflamma-
tion, and their classical activation pathway is activated
mainly by IFN-γ and LPS. M1 macrophages play many
Fig. 5 a Potential mechanism of action of soluble sialic acid-binding immunoglobulin-type lectin (sSiglec)-9 in murine macrophages. Sialidase
was used to assess the effects of eliminating sialic acid from the cell surface on sSiglec-9 efficacy. sSiglec-9 treatment suppressed the messenger
RNA (mRNA) expression of M1 markers. However, pretreatment with sialidase significantly blunted the suppressive effect of sSiglec-9, suggesting
that sSiglec-9 required sialic acid to bind to its receptor. Pretreatment of cells with RS504393, a specific inhibitor for C-C chemokine receptor type
2 (CCR2), did not affect the suppressive effect of sSiglec-9, suggesting that CCR2 was not the primary receptor for sSiglec-9. *p < 0.05, **p < 0.01
(Bonferroni post hoc test). b Effects of sSiglec-9 on mRNA expression of M1 macrophage markers in RAW264.7 cells and peritoneal macrophages
(pMACs). mRNA expression of M1 macrophage markers (tumor necrosis factor [TNF]-α, interleukin [IL]-6, and inducible nitric oxide synthase [iNOS])
was determined by real-time polymerase chain reaction (RT-PCR). Cells were stimulated with interferon (IFN)-γ in the presence or absence of sSi-
glec-9 (0–20 ng/ml) for 12 h. Expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA was used as a control. mRNA expression of all
M1 markers was significantly suppressed by sSiglec-9 treatment in both cell types. *p < 0.05, **p < 0.01 versus samples stimulated with IFN-γ without
sSiglec-9 treatment (Bonferroni post hoc test). c Effects of sSiglec-9 on mRNA expression of M2 macrophage markers in RAW264.7 cells and pMACs.
mRNA expression of M2 macrophage markers (CD206, Arginase-1, and IL-10) was determined by RT-PCR under the same conditions as described above
for M1 markers. mRNA expression of all M2 markers did not significantly change with sSiglec-9 treatment in both cell types (Bonferroni post hoc test).
n.s. not significant
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important roles in the early phase of innate immunity
and function as effector cells in Th1 cellular immune re-
sponses, producing large amounts of TNF-α, IL-12, IL-
23, and iNOS [30]. In the experiments using RAW264.7
cells and pMACs, sSiglec-9 effectively suppressed the ex-
pression of M1 markers. There was no apparent differ-
ence between cell lines and primary macrophages in
response to sSiglec-9 treatment. However, unlike in the
SCI model, M2 macrophage markers did not increase
with sSiglec-9 treatment. Thus, the effects of sSiglec-9
differ across diseases and animal models, and sSiglec-9
suppresses the activation of M1 macrophages in the CIA
mice model.
The mechanism of action of sSiglec-9 and its receptor
are unknown. In a study by Matsubara et al. [15], the de-
pletion of CCR2, treatment with a selective CCR2 inhibi-
tor, and the genetic knockout of CCR2 abolished the
effects of sSiglec-9 on bone marrow-derived macro-
phages. In our in vitro model, however, CCR2 blockade
did not abolish the effects of sSiglec-9. Thus, the pri-
mary receptor for sSiglec-9 is unlikely to be CCL2 in
macrophages. Instead, CCR2 blockage appears to aug-
ment the suppression of IFN-γ-induced M1 marker ex-
pression. CCL2, a ligand for CCR2, is an inflammatory
chemokine that is highly present in the serum of pa-
tients with RA relative to the serum of those with osteo-
arthritis [31], and a positive correlation has been
reported between serum CCR2 concentration and RA
disease activity [32]. Thus, inhibition of the CCR2/CCL2
pathway may more effectively suppress M1 macrophage
activity and disease activity in CIA. Further studies are
needed to identify the primary receptor for sSiglec-9 and
the contribution of the CCR2/CCL2 pathway in the
pathogenesis of CIA.
Matsubara et al. [15]’s work also suggests that sSiglec-
9 binds sialylated carbohydrates on CCR2, inducing an
M2 shift, which can be prevented by removing sialic acid
with sialidase. Consistent with this, sialidase abolished
the ability of sSiglec-9 to inhibit stimulated macro-
phages. These results underscore the importance of the
binding of sSiglec-9 to its receptor via sialic acid, al-
though this receptor has yet to be identified in the CIA
model.
In the present study, IFN-γ was used to stimulate
RAW264.7 cells and pMACs. This cytokine has a
strong inflammatory effect and elicits an immune re-
sponse in mammals. It has a wide range of activities in
distinct cell populations, including both immune and
nonimmune cells. For instance, IFN-γ-primed macro-
phages exhibit increased migration mediated by the
CCR2/CCL2 pathway. IFN-γ-induced, signal transducer
and activator of transcription 1 (STAT1)-independent
pathways result in the activation of phosphoinositide
3-kinase, Akt, p38, protein kinase C, inhibitor of kB
kinases, and STAT3, and they have important func-
tions both in vitro and in vivo, including the promo-
tion of inflammation and cell proliferation [33]. In the
present study, sSiglec-9 did not suppress p38 phos-
phorylation, but it significantly suppressed NF-kB
phosphorylation. Additionally, pretreatment with
celastrol, a selective NF-kB inhibitor, almost com-
pletely suppressed the IFN-γ-mediated induction of
TNF-α mRNA expression. The NF-kB signaling path-
way is involved in the pathogenesis of inflammatory
arthritis, including RA [22]. Collectively, these find-
ings suggest that sSiglec-9 effectively suppresses M1
macrophage activation by downregulating the NF-kB
pathway.
Fig. 6 Effect of soluble sialic acid-binding immunoglobulin-type lectin (sSiglec)-9 on the messenger RNA (mRNA) expression of matrix metalloproteinase
(MMP)-1, MMP-3, MMP-13, and interleukin (IL)-6 in fibroblast-like synoviocytes (FLS) derived from synovial tissue of patients with rheumatoid arthritis. FLS
were stimulated with tumor necrosis factor (TNF)-α in the presence or absence of sSiglec-9 (0–20 ng/ml) for 12 h. Relative mRNA expression of MMP-1,
MMP-3, MMP-13, and IL-6 standardized using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was determined by real-time polymerase chain reaction.
a, b, c, d sSiglec-9 treatment had no effect on the TNF-α-stimulated induction of MMP-1, MMP-3, MMP-13, and IL-6 mRNA expression
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Murine Siglec-E, which corresponds to human Siglec-
9, inhibits Toll-like receptor (TLR)-induced NF-kB, and
negatively regulates TLR responses, including the down-
stream production of TNF-α and IL-6. The expression
of Siglec-E can be induced by LPS or IFN-β (but not
IFN-γ) [34]. In one report, Siglec-H (also murine CD33-
related Siglec) was found to be upregulated by IFN-γ in
microglia, with polarization shifting to M1 [35]. These
data imply that sSiglec-9 may bind to a TLR-related re-
ceptor induced by IFN-γ and downregulate NF-kB
activity.
Synovial tissues in patients with RA consist of synovial
macrophages and FLS. FLS are also considered a key cell
type that mediates the destruction of cartilage and bone
in affected joints [36]. Activation of local FLS is driven
by both proinflammatory cytokines and cytokine-
independent pathways, including endogenous retroviral
elements and TLRs [37]. We examined the expression of
MMP-1, MMP-3, MMP-13 and IL-6, since FLS are the
primary source of MMP expression in RA. MMPs are
structurally and functionally related enzymes and are
subdivided into five groups depending on their matrix
protein substrates. Collagenases (MMP-1 and MMP-13)
and stromelysin (MMP-3) are important for the degrad-
ation of cartilage in RA. Their synthesis and activation
are induced by various factors, including proinflamma-
tory cytokines and TLR ligands [38, 39].
sSiglec-9 did not exert its beneficial effects on FLS
stimulated with TNF-α. Thus, the inhibitory effect of
sSiglec-9 likely occurs via the suppression of M1 macro-
phages, but not local FLS activation, implying that
sSiglec-9 may regulate systemic immune responses in in-
flammatory diseases.
There are some limitations of this study. First, sSiglec-9
had an anti-inflammatory effect in macrophages, but not
in FLS, in vitro. It is possible that other immune cells,
such as neutrophils or T cells other than macrophages, are
targets of sSiglec-9. This possibility, as well as the receptor
for sSiglec-9 and downstream signaling pathways, needs
to be assessed in future studies. Second, we did not assess
the safety profile of sSiglec-9 in this study. sSiglec-9 may
have an immunosuppressive effect, given its ability to sup-
press macrophage activity. Therefore, infectious diseases
or neoplasms are a possibility with sSiglec-9 therapy.
However, none of the animals used in this study had an
infectious disease or neoplasm after treatment with
sSiglec-9, although the treatments were short-term. Fur-
ther studies are needed to assess the long-term safety pro-
file of sSiglec-9 before its use in humans.
Conclusions
sSiglec-9 significantly reduced the incidence and severity
of arthritis in a CIA mouse model. It also reduced M1
macrophage activation via NF-kB suppression in vitro.
Given that many patients do not adequately respond to
currently available biologics, this new agent could con-
tribute to RA treatment strategies via a new mechanism
of action.
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